Trial Profile
Phase 2B Single-site, Open-label, Nonrandomized Study Evaluating the Efficacy of Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jun 2019
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 01 Feb 2019 Status changed from recruiting to completed.
- 27 Mar 2018 Planned primary completion date changed from 1 Feb 2018 to 1 Feb 2019.
- 14 Feb 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.